Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Allogene Therapeutics Inc (NQ: ALLO )

5.360 -0.010 (-0.19%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 21, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,298,808
Open 5.370
Bid (Size) 5.300 (5)
Ask (Size) 5.480 (10)
Prev. Close 5.370
Today's Range 5.340 - 5.545
52wk Range 5.270 - 17.49
Shares Outstanding 142,183,418
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Benzinga's Top Ratings Upgrades, Downgrades For March 21, 2023
 
Via Benzinga
10 Analysts Have This to Say About Allogene Therapeutics
 
Via Benzinga

Performance

YTD
-6.94%
-6.94%
1 Month
-19.76%
-19.76%
3 Month
-14.92%
-14.92%
6 Month
-59.85%
-59.85%
1 Year
-43.52%
-43.52%

More News

Read More
Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-316 at the American Association of Cancer Research (AACR) Annual Meeting
From Allogene Therapeutics, Inc.
Via Globe NewsWire
Allogene Therapeutics's Return On Capital Employed Insights
Via Benzinga
What 10 Analyst Ratings Have To Say About Allogene Therapeutics
Via Benzinga
5 Analysts Have This to Say About Allogene Therapeutics
Via Benzinga
Expert Ratings for Allogene Therapeutics
Via Benzinga
Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds?
Via News Direct
Topics Economy
Exposures Supply Chain
Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds?
Via TheNewswire.com
Topics Economy
Exposures Supply Chain
Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds?
Via Benzinga
Allogene Therapeutics Announces Participation in Two Upcoming Investor Conferences
From Allogene Therapeutics, Inc.
Via Globe NewsWire
Allogene Therapeutics Announces Publication of Industry-Advancing Case Study on Chromosomal Rearrangement in Molecular Therapy
From Allogene Therapeutics, Inc.
Via Globe NewsWire
Allogene Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
From Allogene Therapeutics, Inc.
Via Globe NewsWire
Allogene Therapeutics to Report Fourth Quarter and Year-End 2022 Financial Results on February 28, 2023
From Allogene Therapeutics, Inc.
Via Globe NewsWire
Short Squeezes Have Returned in 2023 -- Here's Your Playbook
Via The Motley Fool
Allogene Therapeutics Presents Data on Dagger™, a Next Generation AlloCAR T™ Platform Technology
From Allogene Therapeutics, Inc.
Via Globe NewsWire
Allogene Therapeutics Publishes Preclinical Data in Clinical Cancer Research Supporting DLL3 as a Potential AlloCAR T™ Target for Small Cell Lung Cancer
From Allogene Therapeutics, Inc.
Via Globe NewsWire
Why Allogene Therapeutics Shares Are Seeing Blue Skies Today
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 24, 2023
Via Benzinga
Allogene Therapeutics Announces Publication in Nature Medicine of Data from its Phase 1 UNIVERSAL Study of ALLO-715 for the Treatment of Relapsed/Refractory Multiple Myeloma
From Allogene Therapeutics, Inc.
Via Globe NewsWire
Amazon To Rally Over 28%? Here Are 10 Other Analyst Forecasts For Tuesday
Via Benzinga
Yext, 1-800-Flowers.com And Other Big Stocks Moving Higher In Tuesday's Pre-Market Session
Via Benzinga
Allogene Therapeutics Announces Participation in Two Upcoming Investor Conferences
From Allogene Therapeutics, Inc.
Via Globe NewsWire
WWE, AMTD Digital And Some Other Big Stocks Moving Higher In Friday's Pre-Market Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2023
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.